Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial

Table 4 Clinical outcomes in TXA trial

Outcomes	TXA (N = 49)	Placebo (N = 51)	HR (95% CI)
Composite outcome within 30 days after surgery^a, n (%)	1 (2.0%)	6 (11.8%)	0.16 (0.02–1.34)
Vascular mortality, n (%)	0 (0.0)	1 (2.0)^b
Non-fatal myocardial infarction, n (%)	1 (2.0%)	3 (5.9%)
Stroke, n (%)	0 (0.0)	0 (0.0)
Pulmonary embolism, n (%)	0 (0.0)	0 (0.0)
Deep vein thrombosis, n (%)	0 (0.0)	1 (2.0)
Life-threatening bleeding, n (%)	0 (0.0)	2 (3.9)
Non-fatal major bleeding, n (%)	0 (0.0)	1 (2.0)
All-cause mortality, n (%)	0 (0.0)	1 (2.0)	–^c
Myocardial infarction, n (%)	1 (2.0%)	4 (7.8%)	0.23 (0.03–2.07)
MINS, n (%)	0 (0.0%)	6 (11.8%)	–^c
Cardiac revascularization, n (%)	0 (0.0)	1 (2.0)	–^c
Postoperative infection, n (%)	6 (12.2)	7 (13.7)	0.77 (0.26–2.30)
Postoperative sepsis, n (%)	1 (2.0)	4 (7.8)	0.23 (0.03–2.04)
Congestive heart failure, n (%)	1 (2.0)	0 (0.0)	–^c
Re-hospitalization for vascular reason, n (%)	0 (0.0)	1 (2.0)	–^c
Seizure, n (%)	0 (0.0)	0 (0.0)	–^c

TXA tranexamic acid, HR hazard ratio, CI confidence interval, MINS myocardial injury after noncardiac surgery
^aComposite outcome of vascular mortality, non-fatal myocardial infarction, non-fatal stroke, non-fatal cardiac arrest, non-fatal pulmonary embolism, non-fatal deep vein thrombosis, non-fatal life-threatening bleeding, and non-fatal major bleeding
^bDue to myocardial infarction
^cNot determinable

ISSN: 2055-5784